PLX Profit Swing Driven by $25M Milestone and Record Net Income in Q1 2026
Q1 2026 Results Show Significant Turnaround With Milestone Revenue Impacting Net Income
Protalix BioTherapeutics (NYSE: PLX) has unveiled a sharp turnaround in its first quarter of 2026, transforming a prior-year net loss into a substantial $18.3 million profit, aided by a one-time $25 million milestone payment from Chiesi for regulatory progress on Elfabrio in Europe. This influx propelled PLX to total revenue of $33.75 million for the quarter, outpacing the $10.11 million recorded a year ago.
Milestone Payment Boosts Earnings, Underlining Strategic Partnership Value
The company’s operational highlight was the European Commission’s approval of the less frequent, 2 mg/kg every-four-weeks (E4W) dosing for Elfabrio—an advancement that not only streamlines Fabry disease treatment but triggered the significant milestone from Chiesi. This payment helped net income per share to surge to $0.23 (basic), compared to a $(0.05) loss last year.
| Q1 2026 ($000s) | Q1 2025 ($000s) | % Change | |
|---|---|---|---|
| Total Revenue | 33,750 | 10,113 | 234% |
| Net Income (Loss) | 18,317 | (3,619) | — |
| Operating Income (Loss) | 21,146 | (4,145) | — |
| Cash, Equiv. & Short-term Deposits | 51,083 | 30,273 | 69% |
Operational Momentum Anchored by Strategic Focus in Rare Diseases
Protalix continues to expand its rare disease portfolio. Elfabrio’s adoption is expected to strengthen across Europe, with the company estimating that the drug could claim 15-20% of the projected $3 billion global Fabry market by 2031. Meanwhile, the phase 2 RELEASE study for PRX-115 (uncontrolled gout) remains on track, with results anticipated in the back half of 2027. The pipeline also includes PRX-119, targeting rare renal disorders.
Guidance Reaffirmed as Revenue Quality Improves
Protalix reaffirmed its full-year 2026 revenue guidance between $78 and $83 million—including the Chiesi milestone. The company expects Elfabrio sales (excluding milestones) between $33 million and $35 million, and Elelyso sales from $20 million to $23 million. Management emphasized a strong balance sheet, with $51 million in liquid assets and no outstanding debt, supporting clinical and commercial priorities.
| 2026 Revenue Components | Guidance ($M) |
|---|---|
| Total Revenue (inc. milestone) | 78 – 83 |
| Elfabrio (product sales only) | 33 – 35 |
| Elelyso | 20 – 23 |
| Milestone from Chiesi | 25 |
Margin Expansion and R&D Investment Reflect Robust Pipeline Commitment
The cost of revenues fell by 50% to $4.13 million, reflecting prior supply chain normalization after elevated Pfizer purchases in the prior year. Research and development expenses rose 56% to $5.43 million, mainly due to the continued advancement of PRX-115. Administrative costs modestly increased, mirroring expanded business activity.
Takeaway: Cash Position, Market Opportunity, and Pipeline Set Up for Long-Term Value
With robust liquidity, no debt, and partnership-driven non-dilutive revenue, Protalix appears well-positioned to finance ongoing trials and future launches. The Q1 milestone-driven profit swing highlights the company’s ability to capitalize on regulatory and commercial catalysts. Investors tracking progress in rare disease therapeutics may want to watch for upcoming data releases, particularly from the PRX-115 program, as further milestones could continue to shape PLX’s financial trajectory.
For additional details, the Q1 2026 conference call replay and webcast are available at Protalix’s investor relations website.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI